Navigation Links
NaturaLens™ Series Hydrophilic Acrylic Intraocular Lens

ProductsNaturaLens™ Series Hydrophilic Acrylic Intraocular Lens
Company Eyekon Medical
Item NaturaLens™ Series Hydrophilic Acrylic Intraocular Lens
Features Inquire
Description Hydrophilic Acrylic Intraocular Lens, AC depth: 4.65.
Info Eyekon Medical
Customer Service: (727) 793-0170
Web site: http://www.eyekonmedical.com

Related medicine products :

1. NaturaLens™ Series Hydrophilic Acrylic Intraocular Lens (Refractive and Bifocal)
2. NaturaLens™ Series Hydrophobic Acrylic Intraocular Lens (Refractive and Bifocal)
3. NaturaLens™ Series Hydrophobic Acrylic Intraocular Lens
4. Series 20000 Legacy
5. Series 24 Watt Sealed CO2 OEM Lasers
6. M/MK Series
7. EA/EKA Series
8. EHS Series
9. MLS-Series Top-Loading Autoclaves
10. Blood Coagulation Analyzer CG Series
11. Cytomics FC 500 Series
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers.
Each handle is designed to fit a specific trephine size.
Each handle is designed to fit a specific trephine size.
Each handle is designed to fit a specific trephine size.
Medicine Products:
(Date:8/7/2008)...gh Tissue Engineering Initiative Marks 12th Year o... PITTSBURGH, Aug. 7 /PRNewswire/ -- Twenty-four u...es, primarily across southwestern Pennsylvania,and...h annual Summer,Internship Program of the Pittsbur...of the program is to expose greatly increased numb...
(Date:8/7/2008)...TY, Aug. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKli...rom the HEAT study show that,once-daily EPZICOM (a... to,once-daily Truvada(R) (tenofovir DF + emtricit... HIV. The data were presented today at the 17th,In...., HEAT is the first large, prospective, long-ter...
(Date:8/7/2008)...N, Aug. 7 /PRNewswire-USNewswire/ -- The U.S. Gove...Development (USAID), is providing,an initial $50,0...emergency,relief supplies to the flood-affected po...ains led to flooding in central and,southeastern T...he capital,of Lome. The UN Development Program est...
(Date:8/7/2008)... Crohn,s disease (CD) are seven-fold more likely t...ses a digestive-tract disease in cattle called Joh...not play in causing CD is a top research priority,...n Academy of Microbiology. The reports points out... role of this bacteriumwhich could conceivably be ...
Breaking Medicine News(10 mins):Health News:Thirty-seven College Students Participate in Regenerative Medicine Summer Research Program 2Health News:Thirty-seven College Students Participate in Regenerative Medicine Summer Research Program 3Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 2Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 3Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 4Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 5Health News:Pathogen that causes disease in cattle also associated with Crohn's disease 2
... of deaths from advanced prostate cancer is to cat...A recent study suggests that effective screening c...is the most frequently diagnosed cancer in men and...by cancer in men in the USA. Many of these cancers...
...id to be able to block the HIV virus from entering... This maybe a major step forward in treatment of...oto, have announce ground braking news in the figh... headed by Hiroaki Mitsuya tried the new drug on 4...
...em are often treated with inhaled nitric oxide// t...at this therapy does not reduce the chances of dea... study are of opinion that premature babies who we...n inhaled nitric oxide therapy unless they are the...
...ceptives maybe at increased risk of heart attack/...k disappears if they stop the pill. The study done... in the July issue of the Journal of Clinical Endo... could have further significance for those women t...
Other Medicine News:Health News:Screening For Prostate Cancer May Reduce Mortality Rate 2Health News:Low-Dose Oral Contraceptives May Increase Risk For Heart Attack Or Stroke 2
(Date:8/7/2008)...e Decision to Expand its Proprietary ...land, Aug. 7 /- ESBATech AG, a leadin...ay announced that the,company has raised an additi...ies B venture round to expand its development pipe...icipated in this round including SV Life,Sciences,...
(Date:8/6/2008)...anently implanted into the heart works,with an ele... patient,s,pulmonary artery pressure, CHICAGO, Au...rtness of,breath are common symptoms that send ten... U.S. hospitals each month. Cardiologists at the B...rial Hospital may be able to,curb such visits for ...
(Date:8/6/2008)...e-FirstCall/ -- GlaxoSmithKline (NYSE:,GSK) (GSK) ...,600 patients,in 54 clinical studies showed no inc...th the anti-HIV medication abacavir. GSK conducted...taken by the D:A:D cohort had found an,unexpected ...tiretroviral,therapy (HAART) regimens containing a...
(Date:8/6/2008)... $15 million payment from collaborator ..., Aug. 6 /- Tolerx, Inc., a,biopharma...lopment of novel,therapies for immune-mediated dis... Phase 3 clinical trial that is evaluating otelixi...a result of the initiation of,patient dosing in DE...
Breaking Medicine Technology:ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing 2ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing 3New Implant Device Remotely Monitors Heart Failure Patients at Northwestern Memorial's Bluhm Cardiovascular Institute 2New Implant Device Remotely Monitors Heart Failure Patients at Northwestern Memorial's Bluhm Cardiovascular Institute 3Pooled-Analysis of 54 Clinical Studies Shows No Increased Risk of Heart Attack With Abacavir Therapy 2Pooled-Analysis of 54 Clinical Studies Shows No Increased Risk of Heart Attack With Abacavir Therapy 3Pooled-Analysis of 54 Clinical Studies Shows No Increased Risk of Heart Attack With Abacavir Therapy 4Pooled-Analysis of 54 Clinical Studies Shows No Increased Risk of Heart Attack With Abacavir Therapy 5Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial 2Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial 3Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial 4Scientists find mercury threatens next generation of loons 13432 1Scientists find mercury threatens next generation of loons 13432 2Hospital Testing for Drug Resistant Infections Dramatically Lowers Mortality Rates and Costs 13429 1Hospital Testing for Drug Resistant Infections Dramatically Lowers Mortality Rates and Costs 13429 2Troubled Boys Will Abandon Pot When Its Deemed Uncool 13426 1Troubled Boys Will Abandon Pot When Its Deemed Uncool 13426 2Imports from Latin America may help US meet energy goals study finds 2400 1Imports from Latin America may help US meet energy goals study finds 2400 2Imports from Latin America may help US meet energy goals study finds 2400 3
...USINESS WIRE)--Jun 13, 2007 - EPIX,Pharmaceuticals...om,its Phase 3 trial of PRX-00023, a novel long-ac...entation at the 47th Annual New,Clinical Drug Eval.... The meeting is sponsored by the National Institu... Psychopharmacology., The presentation highlighted...
...--(BUSINESS WIRE)--Jun 14, 2007 - Can-Fite,BioPhar...the Tel,Aviv Stock Exchange Exchange, proceeds wit... in addition to CF101, which is currently,in clini...es. This,weekend Can-Fite will present at the EUAL...vivo study results showing effective,anti-inflamma...
Other Medicine Technology:EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 2EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 3EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 4Can-Fite Proceeds with Development of Third Drug; Progress in,Development of CF502 Will Be Presented at the Annual European,Congress of Rheumatology 2